Mettler Toledo income statement
In fiscal 2025, Mettler Toledo reported revenue of $4.03bn, up 4.0% on the year before and net income of $869m, or $42.05 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,729 | 1,968 | 2,309 | 2,342 | 2,379 | 2,486 | 2,395 | 2,508 | 2,725 | 2,936 | 3,009 | 3,085 | 3,718 | 3,920 | 3,788 | 3,872 | 4,026 | 4,134 |
| Gross profit | 889 | 1,037 | 1,218 | 1,241 | 1,282 | 1,359 | 1,352 | 1,438 | 1,576 | 1,684 | 1,741 | 1,801 | 2,172 | 2,308 | 2,241 | 2,326 | 2,391 | 2,491 |
| Research and development | 90 | 97 | 116 | 113 | 116 | 123 | 119 | 119 | 128 | 141 | 144 | 140 | 170 | 177 | 185 | 189 | 199 | 208 |
| Selling, general and administrative | 505 | 589 | 704 | 684 | 693 | 729 | 701 | 745 | 795 | 813 | 819 | 820 | 944 | 938 | 904 | 936 | 998 | 1,030 |
| Interest expense | 25 | 20 | 23 | 23 | 23 | 25 | 27 | 28 | 33 | 35 | 37 | 39 | 43 | 55 | 77 | 75 | 69 | 69 |
| Income before tax | 225 | 308 | 349 | 383 | 403 | 445 | 463 | 504 | 574 | 652 | 681 | 749 | 949 | 1,071 | 974 | 1,037 | 1,049 | 1,097 |
| Income tax | 52 | 75 | 80 | 92 | 97 | 107 | 111 | 120 | 198 | 139 | 120 | 146 | 180 | 198 | 185 | 174 | 180 | 192 |
| Net income | 173 | 232 | 269 | 291 | 306 | 338 | 353 | 384 | 376 | 513 | 561 | 603 | 769 | 873 | 789 | 863 | 869 | 906 |
| Diluted EPS | $5.03 | $6.80 | $8.21 | $9.14 | $9.96 | $11.44 | $12.48 | $14.22 | $14.24 | $19.88 | $22.47 | $24.91 | $32.78 | $38.41 | $35.90 | $40.48 | $42.05 | $44.44 |
| Diluted shares (average) | 34m | 34m | 33m | 32m | 31m | 30m | 28m | 27m | 26m | 26m | 25m | 24m | 23m | 23m | 22m | 21m | 21m | 20m |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 955 | 1,045 | 884 | 983 | 1,030 | 1,130 | 947 | 1,027 |
| Gross profit | 572 | 639 | 526 | 580 | 609 | 675 | 556 | 650 |
| Research and development | 47 | 50 | 46 | 49 | 51 | 53 | 51 | 53 |
| Selling, general and administrative | 229 | 237 | 243 | 247 | 248 | 260 | 258 | 263 |
| Interest expense | 19 | 18 | 17 | 17 | 18 | 17 | 17 | 17 |
| Income before tax | 259 | 315 | 202 | 249 | 269 | 329 | 210 | 289 |
| Income tax | 47 | 62 | 38 | 46 | 52 | 43 | 40 | 57 |
| Net income | 212 | 252 | 164 | 202 | 217 | 286 | 169 | 233 |
| Diluted EPS | $9.96 | $11.93 | $7.81 | $9.76 | $10.57 | $13.93 | $8.33 | $11.55 |
Compare with peers
- Charles River Laboratories income statement
- Illumina, Inc. income statement
- Waters Corporation income statement
- Bruker Corp income statement
- Medpace Holdings, Inc. income statement
Head to head: CRL vs MTDILMN vs MTDMTD vs WATBRKR vs MTD
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies